Holen Sie sich die Stockscreener-App
160.12
0.55%
-0.89
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - Novartis
Skeletal Dysplasia Market - GlobeNewswire Inc.
Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market - GlobeNewswire Inc.
What's Driving the Market Sentiment Around Novartis AG? - Sahm
Novartis Stock: Can New Cancer Bets Keep Beating Big Pharma? - AD HOC NEWS
Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement - Sahm
Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas - Finviz
NVS Earnings History & Surprises | EPS & Revenue Results | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Avidity Biosciences shareholders approve merger with Novartis - Investing.com
Novartis stock hits all-time high at 167.87 USD - Investing.com
Stocks To Watch, February 20: Swiggy, IT stocks, crude-sensitive stocks, Novartis India, ABB India, CIE Automotive, Zydus Life - Upstox
Where is Novartis AG (NVS) Headed? - Finviz
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals - ChartMill
A Look Into Novartis Inc's Price Over Earnings - Sahm
Novartis AG stock reaches all-time high at 160.21 USD - Investing.com Nigeria
Novartis AG stock reaches all-time high at 160.21 USD By Investing.com - Investing.com South Africa
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz
IgA Nephropathy Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences - Barchart.com
Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com Nigeria
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead - Sahm
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Novartis stock hits all-time high at 153.83 USD By Investing.com - Investing.com Australia
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales - Finviz
Novartis stock hits all-time high at 153.83 USD - Investing.com
Earnings call transcript: Novartis Q4 2025 earnings beat forecasts, stock jumps - Investing.com
Peering Into Novartis AG's Recent Short Interest - Sahm
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Sahm
Why Analysts Are Closely Watching Novartis AG (NVS) - Finviz
Jim Cramer is Optimistic About Novartis' (NVS) Cancer Drug - Finviz
Novartis Shares Test 12-Month Highs on Bullish New Outlook - AskTraders.com
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Novartis Positions US Strategy As Defense Against Rising Trade Levies - Sahm
Novartis stock hits all-time high at $146.4 By Investing.com - Investing.com South Africa
Novartis stock hits all-time high at $146.4 - Investing.com
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals - Chartmill
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Novartis ADR: Defensive Giant Tests Investor Patience As Rally Cools - AD HOC NEWS
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case - Chartmill
Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub - Finviz
1.67%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):